molecules of the month


oral prodrug of IDO1 inhibitor

completed Ph. I in solid tumors

from derivatization of indoximod

Eur. J. Med. Chem., May 1, 2020

NewLink Genetics, Ames, IA

Structure of NLG802, a prodrug of indoximod
1 min read

NLG802 is a prodrug of the IDO1 inhibitor indoximod with significantly enhanced oral exposure. Both the acid and amine functionalities of indoximod are protected as an ethyl ester and leucine amide, respectively. Prodrugs are generally difficult to develop so it’s interesting that two biotransformations are employed. The molecule is first cleaved to the carboxylic acid by carboxyesterases CES1b and CES1c, which is then further cleaved by unidentified peptidases to release indoximod.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: